Can I Take Green Tea Extract (EGCG) with Rezdiffra (Resmetirom)?

What Is Resmetirom and Why Does Liver Safety Matter?

Resmetirom is the first FDA-approved oral therapy specifically for metabolic dysfunction-associated steatohepatitis (MASH) with liver fibrosis. It works by selectively activating thyroid hormone receptor beta (THR-beta) in hepatocytes, which shifts hepatic fat metabolism and reduces lipogenesis without significant systemic thyroid effects [1]. Because it acts directly inside already-injured liver cells, any co-administered agent that independently stresses those same cells creates compounding risk.

The MAESTRO-NASH Trial Baseline

The phase 3 MAESTRO-NASH trial (N=966, 52 weeks) demonstrated that resmetirom 100 mg produced NASH resolution in 25.9% of patients versus 14.2% on placebo, and fibrosis improvement by at least one stage in 29.9% versus 19.9% on placebo [2]. ALT elevations above three times the upper limit of normal occurred in a small but non-trivial subset of participants, underscoring that the drug itself carries a hepatic adverse event profile that demands careful co-medication screening.

How Resmetirom Is Metabolized

Resmetirom is primarily transported into hepatocytes via OATP1B1 and OATP1B3 (encoded by SLCO1B1 and SLCO1B3) and is metabolized predominantly by CYP2C8, with minor contributions from CYP3A4 [1]. Inhibition of either the transporter or CYP2C8 could increase systemic exposure and amplify hepatotoxicity risk. This metabolic profile is directly relevant to EGCG, as discussed below.

What Is EGCG and Why Is Its Liver Safety Profile Complicated?

Epigallocatechin gallate (EGCG) is the principal catechin in green tea and the dominant bioactive constituent in most green tea extract (GTE) supplements. At the concentrations found in brewed tea (roughly 50-100 mg per 240 mL cup), EGCG is not associated with liver injury in population-based studies [3]. The risk shifts substantially with concentrated supplement forms, where single-capsule doses often reach 400-800 mg of EGCG per serving.

Green Tea Extract and Drug-Induced Liver Injury

The U.S. Pharmacopeia (USP) reviewed 216 case reports and identified a causality signal strong enough to add a cautionary monograph warning to GTE products [4]. A systematic review published in Drug Safety (Mazzanti et al., 2015) catalogued 34 published case reports of GTE-associated DILI, with onset typically within 1 to 3 months of starting the supplement [5]. Liver biopsy findings in confirmed cases showed hepatocellular necrosis patterns consistent with mitochondrial dysfunction, a proposed mechanism involving EGCG-driven reactive oxygen species (ROS) generation at high intracellular concentrations [5].

The FDA MedWatch database contains over 80 case reports linking green tea extract products to liver injury, some requiring transplantation [6]. That signal led the European Food Safety Authority (EFSA) to conclude in 2018 that GTE doses above 800 mg EGCG per day are associated with a "possible risk" of liver injury, while doses below 800 mg/day in a fed state carry lower but not zero risk [7].

Dose Dependency Is Real but Not Fully Protective

Not every patient who takes high-dose GTE develops DILI. Susceptibility appears to involve NAD(P)H quinone oxidoreductase 1 (NQO1) polymorphisms, fasting state at the time of ingestion, and baseline liver health [5]. That last factor is especially relevant: patients with MASH already have elevated hepatocellular oxidative stress, impaired mitochondrial function, and reduced antioxidant reserve, precisely the conditions that may lower the threshold for EGCG-triggered injury.

The Pharmacokinetic Interaction: OATP Transporters and CYP2C8

This is where the interaction moves beyond theoretical. EGCG is a known inhibitor of OATP1B1 and OATP1B3, the same hepatic uptake transporters that carry resmetirom from portal blood into hepatocytes [8]. Inhibiting these transporters could reduce hepatic uptake of resmetirom, lowering its intrahepatic concentration and potentially blunting therapeutic effect, while simultaneously raising systemic plasma concentrations of resmetirom, which could amplify off-target effects.

In Vitro Evidence for OATP Inhibition

A 2019 study by Misaka et al. In European Journal of Pharmaceutical Sciences demonstrated that EGCG inhibited OATP1B1-mediated uptake of reference substrates in transfected HEK293 cells at concentrations achievable in portal blood after GTE supplementation (IC50 approximately 7.4 micromolar) [8]. A follow-up pharmacokinetic study in healthy volunteers given green tea extract showed a 1.4-fold increase in the AUC of atorvastatin, an established OATP1B1/1B3 substrate, confirming that the in vitro signal translates to humans [9].

CYP2C8 Considerations

EGCG has shown inhibitory activity against CYP2C8 in human liver microsome studies, though the Ki values reported (approximately 15-40 micromolar) require high portal concentrations to reach clinical significance [10]. At typical supplement doses, CYP2C8 inhibition is likely modest. The OATP transporter interaction is the more established concern for resmetirom specifically.

Classifying the Interaction: Pharmacodynamic vs. Pharmacokinetic

The resmetirom-EGCG interaction has two distinct and simultaneous components.

Pharmacodynamic (additive hepatotoxicity): Both resmetirom and high-dose GTE can independently raise liver enzymes and cause hepatocellular stress. Taking them together in a patient whose liver already meets MASH criteria stacks these risks in a setting where the liver has reduced repair capacity. This is a class C pharmacodynamic interaction using the Hansten-Horn Drug Interaction Classification system.

Pharmacokinetic (transporter-mediated): EGCG inhibits OATP1B1 and OATP1B3, potentially altering resmetirom distribution between plasma and hepatic tissue. The net clinical consequence could be reduced therapeutic effect or increased systemic drug exposure, depending on the degree of inhibition achieved at portal vein concentrations after a given GTE dose.

Neither mechanism alone is reason for absolute contraindication in every patient. Together, in a person with established MASH-related fibrosis, they justify a clear clinical recommendation: avoid high-dose GTE supplements during resmetirom therapy.

What the Resmetirom Prescribing Label Says

The FDA-approved prescribing information for Rezdiffra (resmetirom) lists OATP1B1/1B3 inhibitors as agents that may increase resmetirom plasma concentrations and advises caution with concomitant use [1]. The label does not name EGCG or green tea extract explicitly, because labeling typically references approved drugs rather than supplements. This gap in labeling does not indicate safety; it reflects the regulatory pathway, not clinical risk assessment.

The label also states: "Monitor liver tests (ALT, AST, total bilirubin, and alkaline phosphatase) prior to initiating Rezdiffra, 3 months after starting, and periodically thereafter" [1]. Adding a supplement that independently elevates these same markers makes monitoring-based safety decisions harder to interpret.

Monitoring Protocol When Both Are Being Taken

If a patient is already taking both resmetirom and GTE supplements before this interaction is identified, the following stepwise approach is appropriate based on published DILI management frameworks from the Drug-Induced Liver Injury Network (DILIN) [11]:

Step 1: Quantify the GTE Dose

Determine the daily EGCG dose from the supplement label. Doses below 300 mg EGCG per day from a standardized, fed-state supplement carry lower risk. Doses above 600 mg per day should be treated with greater concern, particularly when liver enzymes are already elevated.

Step 2: Check Current Liver Enzymes

Obtain ALT, AST, total bilirubin, and alkaline phosphatase. Per the DILIN consensus, an ALT above five times the upper limit of normal, or any elevation in bilirubin combined with an ALT above three times normal (Hy's Law criteria), warrants immediate discontinuation of the suspected hepatotoxin [11].

Step 3: Discontinue GTE First

Because resmetirom is the FDA-approved treatment for a progressive fibrotic liver disease, it holds higher therapeutic priority than a supplement. Stop GTE and recheck liver enzymes in two to four weeks. If values normalize, resmetirom may be continued with enhanced monitoring.

Step 4: Report Adverse Events

Clinicians and patients should report suspected GTE-associated DILI to FDA MedWatch at fda.gov/safety/medwatch [6]. The more case reports that enter the database, the faster the FDA can update guidance on this specific combination.

Culinary Green Tea vs. Supplement-Form GTE: Not the Same Risk

A standard 8-ounce cup of brewed green tea contains approximately 50-100 mg of EGCG, compared to a single GTE supplement capsule that may contain 400-800 mg [3]. Three cups of brewed green tea per day delivers roughly 150-300 mg EGCG, a dose substantially below the EFSA's 800 mg concern threshold [7].

Population-level evidence supports the distinction. A large prospective cohort study from the Ohsaki National Health Insurance Cohort (N=40,530) found that habitual green tea consumption of 5 or more cups daily was associated with reduced all-cause mortality and was not associated with liver injury signals [12]. The risk profile of encapsulated, standardized extracts delivering concentrated EGCG does not extrapolate to moderate brewed tea consumption.

For patients on resmetirom who enjoy green tea as a beverage, 1-3 cups per day is generally considered acceptable, provided liver enzyme monitoring continues per the standard Rezdiffra protocol. This should be confirmed with the prescribing clinician, especially in patients with F3 fibrosis or elevated baseline ALT.

What Alternatives to GTE Are Safer for MASH Patients on Resmetirom?

Patients often seek supplements to complement MASH treatment. Some have better safety profiles than GTE in the context of active liver disease:

• Vitamin E (800 IU/day alpha-tocopherol): Studied in the PIVENS trial (N=247) for non-diabetic NASH patients, showing histologic improvement versus placebo [13]. No known pharmacokinetic interaction with resmetirom.
• Omega-3 fatty acids (icosapentaenoic acid / docosahexaenoic acid): Generally well tolerated in liver disease; no established transporter interaction with resmetirom at standard doses of 2-4 g/day.
• Coffee (unfiltered or filtered): Epidemiological data consistently link 2-3 cups daily with lower rates of fibrosis progression in NAFLD/MASH without any pharmacokinetic concern for resmetirom [14].

None of these alternatives should be started without discussing with the treating hepatologist or gastroenterologist, because MASH patients often have multiple comorbidities requiring individualized risk assessment.

Clinical Decision Framework: Green Tea Extract + Resmetirom Risk Stratification

The following framework integrates hepatotoxicity risk, OATP interaction magnitude, and patient-specific fibrosis stage:

Low concern: Brewed green tea, 1-3 cups per day, baseline ALT within normal limits, F2 fibrosis. Continue with standard monitoring.

Moderate concern: GTE supplement at 200-400 mg EGCG per day, ALT up to two times the upper limit of normal, F2-F3 fibrosis. Discuss discontinuation of GTE; increase liver enzyme monitoring to monthly.

High concern: GTE supplement at 400 mg or more EGCG per day, or any ALT elevation above three times the upper limit of normal, or F3 fibrosis, or co-administration of other OATP1B1 inhibitors (e.g., cyclosporine, rifampin). Discontinue GTE immediately; do not restart without hepatologist clearance.

A 2021 analysis from the LiverTox database at the National Institutes of Health classified green tea extract as a "likely" cause of clinically apparent liver injury with a likelihood score of A, the highest category in their rating system [15]. That classification applies to concentrated supplement forms, not to brewed tea.

Practical Guidance for Patients and Prescribers

Patients currently taking Rezdiffra should bring every supplement bottle to their next appointment. The prescribing clinician needs the supplement name, the EGCG content per serving, and the daily dose the patient is actually taking, not just the serving size on the label.

Prescribers writing a new resmetirom prescription should ask directly about GTE and other antioxidant supplements during the medication reconciliation process. The supplement is sold under dozens of brand names including Teavigo, Sunphenon, and various private-label GTE products, and patients frequently do not mention supplements unprompted because they consider them food rather than medicine.

The American Association for the Study of Liver Diseases (AASLD) 2023 NAFLD/MASH practice guidance states: "Patients with MASH should be counseled to avoid herbal supplements and dietary supplements that have established or suspected hepatotoxic potential" [16]. Green tea extract meets that criteria based on the published DILI record.

Summary of the Key Evidence Points

The case against combining high-dose GTE with resmetirom rests on four converging lines of evidence:

1. GTE at doses above 800 mg EGCG per day carries a documented DILI risk, with over 80 MedWatch case reports and an EFSA safety review confirming the signal [6, 7].
2. EGCG inhibits OATP1B1 and OATP1B3 in vitro at portal-vein-achievable concentrations, with clinical confirmation in a human atorvastatin pharmacokinetic study [8, 9].
3. Resmetirom depends on OATP1B1/1B3 for hepatic uptake and is metabolized by CYP2C8, both pathways subject to EGCG inhibition [1, 10].
4. MASH patients have reduced hepatic resilience to oxidative stress, lowering the injury threshold for any hepatotoxic insult [2].

Taken together, these data support a clear clinical recommendation: patients on resmetirom should avoid concentrated GTE supplements, maintain monitoring per the Rezdiffra prescribing label, and report any new symptoms of liver injury (right upper quadrant pain, jaundice, dark urine, fatigue) promptly. In the MAESTRO-NASH trial, the 100 mg resmetirom dose produced a mean ALT reduction of 22.6 IU/L from baseline at 52 weeks [2]. Introducing a hepatotoxic supplement risks erasing that benefit and triggering treatment discontinuation.